CorEvitas is now part of Thermo Fisher Scientific. Read More.
NOW ENROLLING
600+
STUDY VISITS
1600+
PATIENTS
70+
DERMATOLOGISTS
Outcome measures in the CorEvitas AD Registry.
In addition to demographics, clinical features, medication history and changes, and comorbidities, key outcome measures collected include:
Clinician Reported Outcomes
Body Surface Area (BSA) Involvement
Eczema Area and Severity Index (EASI)
SCORing Atopic Dermatitis (SCORAD)
Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD)
Nail changes due to atopic dermatitis (graduated Visual Analogue Scale)
Patient Reported Outcomes
Patient global assessments of disease control and severity
Dermatology Life Quality Index (DLQI)
Patient-Oriented Eczema Measure (POEM)
Atopic Dermatitis Control Tool (ADCT)
Peak pruritus Numerical Rating Scale
Sleeplessness and average pruritus (SCORAD)
Skin Pain Numerical Rating Scale
Fatigue Numerical Rating Scale
Itch triggers (PROMIS)
Work Productivity and Activity Impairment (WPAI)
Active safety assessments using structured data fields are collected with supporting documents to meet regulatory requirements and post marketing commitments of manufacturers.
